FOxTROT: neoadjuvant FOLFOX chemotherapy in colorectal cancer

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, provides an overview of the Phase III FOxTROT trial (NCT00647530), which assessed neoadjuvant chemotherapy in patients with locally advanced colorectal cancer. Patients received either neoadjuvant FOLFOX followed by surgery and more chemotherapy, or the standard of care with only surgery and post-operative chemotherapy. Disease-free survival (DFS), the primary endpoint, was met, and patients with T4 tumors benefited the most, whereas microsatellite instability high (MSI-H) patients tended to have poorer outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ